An assessment of the characteristics and quality of diagnostic accuracy studies for positron emission tomography conducted in Japan: a systematic review by unknown
Nomura et al. EJNMMI Research  (2015) 5:6 
DOI 10.1186/s13550-015-0084-4ORIGINAL RESEARCH Open AccessAn assessment of the characteristics and quality of
diagnostic accuracy studies for positron emission
tomography conducted in Japan: a systematic
review
Shuhei Nomura1,3*, Akinori Hisashige2, Daisuke Yoneoka1, Mikiko Kanda1, Karin Miyamoto1, Miwako Segawa1,
Erika Ota1 and Kenji Shibuya1Abstract
Background: Systematic evaluations of the diagnostic accuracy of positron emission tomography (PET) imaging
have been widely conducted in many countries. Although Japan’s total number of PET units is the second highest
in the world, very limited effort has been made to systematically assess the methodological quality of PET studies in
Japan. We performed a systematic review to assess the characteristics and quality of PET diagnostic accuracy
studies conducted in Japan and to analyze the factors related to their quality.
Methods: All PET studies conducted in Japan were identified using MEDLINE and the Japan Medical Abstract
Society Database. The characteristics of the Japanese studies were examined and their methodological quality
evaluated by the standardized quality assessment of diagnostic accuracy studies (QUADAS) tool. We compared the
quality of studies indexed in MEDLINE with non-indexed studies, followed by a comparison of the studies’ conclusions
with those of international health technology assessment (HTA) reports.
Results: A total of 138 studies were identified. Half of them were not indexed in MEDLINE. The mean quality score of
the Japanese studies was 6.7 and the proportion of high-quality studies (with a quality score higher than 8) was 32.6%.
A significant difference was observed in several quality items between MEDLINE-indexed and non-indexed studies,
although there was no difference in total quality score. Three variables (i.e., target diseases, publication year, and study
type) were identified as factors related to the quality of the studies. Conclusions of Japanese studies relating to several
target diseases were relatively consistent with international assessments.
Conclusions: Although a considerable number of diagnostic accuracy studies of PET have been conducted in Japan, a
substantial proportion of high-quality studies were not indexed in international databases. High-quality Japanese
studies, therefore, should be searched using Japanese databases and assessed by systematic reviews and HTA
conducted internationally.
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Positron emission tomography (PET) is a noninvasive
imaging technique used for measuring the concentration
of positron-emitting radioisotopes within tissue in malig-
nant and benign disease and provides a three-dimensional
image of functional changes in the body. PET can be used
to assist management decisions related to diagnosis, sta-
ging/restaging, recurrence, and treatment planning and
response as well as prognosis. Recently, an increasing
number of clinical applications of PET have been ob-
served, particularly in oncology, and mostly with the use
of fluorine-18 fluorodeoxyglucose (18 F-FDG) as the PET
tracer [1,2].
PET, however, is a high-cost technology, and it is
therefore important for health policymakers to systemat-
ically assess not only the clinical indications of PET but
also its cost-effectiveness in comparison with other com-
petitive diagnostic technologies [3]. To this end, various
countries have evaluated the efficacy and efficiency of
PET since its introduction and diffusion into clinical
practice [4-6].
In this evaluation, both diagnostic accuracy and
methodological quality of diagnostic studies are im-
portant elements of this evaluation. However, diagnos-
tic studies have several unique features in terms of
quality, which are not addressed by the traditional ap-
proach to evaluating controlled trials. A validated qual-
ity assessment tool is currently not available [7]. In
2003, the Standards for the Reporting of Diagnostic
Accuracy (STARD) statement was developed to help
authors improve reporting [8], and the quality assess-
ment of diagnostic accuracy studies (QUADAS) tool
was developed in the same year [9]. Despite these ad-
vancements and the development of study selection
tools for systematic reviews [4,6,10,11], comprehensive
quality assessment of PET diagnostic studies has been
very limited.
In Japan, while PET has been introduced and diffused
without a systematic health technology assessment, the
total number (i.e., 466) of PET units installed in Japan
was the second highest in the world following the
United States (i.e., 1,450) in 2011 [12]. A considerable
number of diagnostic studies for PET have been con-
ducted, but as they are primarily published in Japanese,
they have not been widely reported in international
journals and databases.
Therefore, even though Japanese studies have made
a contribution to the evaluation of diagnostic accur-
acy of PET both in Japan and internationally, com-
prehensive information about PET studies conducted
in Japan is greatly lacking. We conducted a system-
atic review to assess the characteristics and quality of
PET studies in Japan and analyze the factors related
to their quality.Methods
Search strategy
All papers reporting diagnostic efficacy studies for
PET conducted in Japan as original articles were iden-
tified through two databases: the international data-
base, MEDLINE, and Ichu-Shi, the domestic Japanese
database of the Japan Medical Abstract Society. MEDLINE
includes Japanese papers written in English, as well as only
English summaries for a very limited number of papers
written in Japanese. We searched this database from in-
ception to 15 July 2011. Ichu-Shi includes studies written
in Japanese and published in Japanese journals and occa-
sionally features an English summary. We searched this
database from inception to 23 August 2011. The search
strategy used the following general terms, expanded and
appropriately modified for each database: ‘positron emis-
sion tomography’ or ‘positron emission computed tomog-
raphy’ or ‘PET’, and ‘sensitivity’ and ‘specificity’. The search
terms are presented in Additional file 1: Table S1 and
Additional file 2: Table S2.
Inclusion and exclusion criteria
All papers reporting diagnostic efficacy or accuracy stud-
ies of PET conducted in Japan that used data from PET
scans performed at institutions in Japan and were pub-
lished as original articles until the end of 2010 were
included. The following types of PET studies were ex-
cluded: 1) non-diagnostic studies, such as studies of
treatment planning, and response and prognosis; 2)
studies that did not explicitly describe sensitivity and/or
specificity of PET, and which could not be derived from
the data provided in the paper; 3) studies written in lan-
guages other than Japanese or English, and 4) case reports,
systematic reviews and meta-analyses.
Study selection and data extraction
Two reviewers independently screened titles and ab-
stracts of studies identified by the search. The text of
all potentially relevant studies was evaluated in detail
and assessed against eligibility criteria. The following
data were extracted and checked independently by two
reviewers: database indexed, publication year, index
test, study type, sample size, target disease, comparator,
study subjects, outcome (i.e., sensitivity and specificity),
conclusions, and funding source. Any disagreements were
resolved by consensus between the reviewers.
Assessment of quality of studies
The QUADAS tool was used to assess the methodo-
logical quality of studies. This tool is a validated quality
checklist containing 14 items that address the most im-
portant sources of bias and variation in diagnostic accur-
acy studies [7,9,13]. QUADAS was also adopted by the
Cochrane Collaboration in their handbook of diagnostic
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14 items were listed in Additional file 3: Table S3.
The reviewers who assessed and extracted data were
trained in the use of the QUADAS checklist. Each item
in the checklist was categorized as ‘Yes’ for low risk of
bias, ‘No’ for high risk of bias, or ‘Unclear’ if there was
insufficient information to make a judgment. We also
calculated a quality score defined as the total number of
items categorized as ‘Yes’ among 14 items.
Data analysis
Firstly, we identified the number of diagnostic efficacy
studies of PET conducted in Japan from 1990 to 2010
and examined their characteristics. Then we assessed the
quality of these studies using the QUADAS tool. Secondly,
we evaluated the quality of these studies by comparing
studies indexed in MEDLINE with studies published in
Japanese journals that were not indexed in international
databases. We used Fisher’s exact test for proportions and
t-test for quality scores in the statistical analysis.
Thirdly, the factors affecting the quality of Japanese
PET studies were analyzed using a multiple logistic re-
gression model. The dependent variable was whether the
quality of the study was high (=1) or low (=0) [15-17].
We defined studies as high quality when the quality
score exceeded eight (i.e., more than a half of total score),
based on a definition from a previous systematic review
[18]. The independent variables were target disease, publi-
cation year, sample size, study design, funding source,
international indexing, and whether or not comparative
statistical analysis was conducted. All analyses were per-
formed with STATA/MP 13.
Finally, the results and conclusions of the Japanese
studies were compared with those of international HTA
reports and systematic reviews in clinical medicine, in re-
lation to PET and other competitive imaging technologies.
We made this comparison to primarily examine the cor-
respondence of the results and conclusions of Japanese
studies with those of the international assessments. In the
comparison, instead of an integrated form, only a propor-
tion of positive conclusions, as well as a quality score and
a proportion of comparative studies, are presented for the
reader’s own consideration since there is no explicit or
standardized guideline for integrating conclusions or
recommendations of accumulated studies. In addition,
we assessed the coverage of different diseases among
both the Japanese studies and international assessments
to examine whether Japanese studies covered some
diseases that international assessments did not. HTA
studies related to PET were comprehensively identified
by database searches (i.e., the Centre for Reviews and
Dissemination (CRD) database, a health services re-
search center based at the University of York). Of the 49
reports identified and retrieved, two Belgian Health CareKnowledge Centre (KCE) reports were selected as a refer-
ence [6,10], which are the latest and most comprehensive
assessments of high quality according to the INAHTA
checklist for HTA reports [19]. We found only one sys-
tematic review that comprehensively covered areas of dis-
ease [11]. Note that as the number of Japanese studies was
limited, we analyzed target diseases that were examined in
more than three of the Japanese studies.
Results
Search results
A total of 691 potentially relevant studies were identified
from database searches (Figure 1). Of these, 269 studies
were evaluated in detail. Finally, a total of 138 studies
were determined to meet eligibility criteria and included
in the analysis. Of the total of 138 included studies, 70
studies were written in Japanese and 68 studies were
written in English, of which 3 studies and 66 studies
were indexed in MEDLINE, respectively.
Characteristics of Japanese studies
Nearly 90% of the studies evaluated malignant neoplasms
and mostly examined lung cancer (21.7%), followed by
head and neck cancer (8.7%) and breast cancer (7.2%),
respectively (Table 1). Of the 39 articles classified into
‘others’, 10 (7.2%) investigated non-malignant diseases or
disorders, such as gallbladder wall thickening, artery oc-
clusive diseases, aortic graft infection, and pneumoconi-
osis. Ninety-six percent of the studies used 18 F-FDG as a
PET tracer. More than half of the studies were published
after 2007. The sample size among 57.9% of the studies
was less than 50. Only one study employed more than 500
patients. Comparative analyses with other competitive
diagnostic technologies, such as MRI and/or CT, were
conducted in 47.8% of the studies. The most frequent type
of study design was the retrospective study (74.6%). Fund-
ing sources were not reported in 88% of the studies.
Methodological quality of Japanese studies
Studies were assessed using QUADAS (Additional file 3:
Table S3). The proportion of studies with high quality,
in which eight or more items were categorized as ‘Yes’
for low risk of bias, was 32.6%. The mean (SD) quality
score out of 14 items was 6.7 (2.5).
As shown in Figure 2, the following 6 of 14 items were
observed to have high risk of bias, where the proportion
of items categorized as ‘No’ was high (more than 50%):
adequate spectrum (item 1), adequate reference standard
(item 3), partial verification (item 5), differential verifica-
tion (item 6), incorporation bias (item 7), and descrip-
tion of reference test execution (item 9). Low risk of
bias, where the proportion of items categorized as ‘Yes’
was high (more than 50%), was observed in the following
five items: selection criteria (item 2), description of the
Figure 1 Flow diagram for study selection.
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pretable results (item 13), and withdrawals (item 14). The
following two items were categorized as ‘Unclear’ due to a
lack of sufficient information to make a judgment: disease
progression (item 4) and clinical review (item 12).
Comparison between MEDLINE-indexed and non-indexed
studies
Figure 3 compares the results in quality between the
MEDLINE-indexed and non-indexed studies. The pro-
portion of items categorized as ‘Yes’ among MEDLINE-
indexed studies was significantly higher than among non-
indexed studies in disease progression, (item 4) (p = 0.009,
30.4% for indexed studies and 8.7% for non-indexed stud-
ies); description of index test execution (item 8) (p < 0.001,
97.1% for indexed studies and 72.5% for non-indexed
studies); and index test review (item 10) (p < 0.001, 75.4%
for indexed studies and 43.5% for non-indexed studies). In
contrast, we observed a lower proportion of ‘Yes’ items in
MEDLINE-indexed studies for the description of reference
test (item 9) (p < 0.001, 21.7% for indexed studies and
49.3% for non-indexed studies). However, there is no
statistical difference in the mean quality score between
them (p = 0.3). Note that as the language type of the
paper closely corresponded to whether or not the study
was indexed in MEDLINE, the differences in methodo-
logical quality between the English and Japanese pa-
pers were similar to those observed between papers
indexed in MEDLINE and those that were not (data
are not shown).
Factors related to the quality of studies
Table 2 shows the result of a multiple logistic regression
analysis to examine the factors related to the methodo-
logical quality. Of all seven factors employed, targetdisease, publication year, and study design were shown
to be associated with study quality. Target diseases
other than respiratory cancer, gastrointestinal cancer,
gynecological cancer, head and neck cancer, and breast
cancer, which were categorized as ‘others’, were lower
in quality (p = 0.02). Studies published between 2003
and 2006 were lower in quality than those published
before 2002 (p = 0.01). The methodological quality of
studies between 2007 and 2010 was also lower than
that before 2002, but the difference was not statistically
significant (p = 0.1). Also, prospective studies were
higher in quality than retrospective studies (p = 0.04).
Comparing the conclusions of Japanese studies and
international HTA reports and systematic reviews
Table 3 shows a comparison between the conclusions of
Japanese studies with international HTA reports and the
systematic review in oncology. While the conclusions in
breast, esophageal, and ovarian cancers were relatively
consistent among Japanese studies and international as-
sessments, those in other target diseases, including lung
cancer, lymphoma, and head and neck cancer, were in-
consistent among them.
In addition, the Japanese studies covered many other
areas of disease (e.g., stomach, cervical, and uterine can-
cers) where evidence and recommendations were lacking
in the international assessments. The number of studies
in Japan varied widely from 4 to 30 depending on disease
areas, and quality scores ranged from 5.7 to 8.8. The pro-
portion of comparative studies also varied widely from
38% to 100%, and the proportion of positive conclusions
ranged from 0% to 75%. The number and quality scores of
studies, and the proportion of comparative studies, were
not necessarily correlated to the proportion of positive re-
sults and the discrepancies among conclusions.
Table 1 Characteristics of included studies by year of
application/revision of the insurance service
Characteristics Number of articles (%)
Diseases
Lung cancer 30 (21.7)
Lymphoma 5 (3.6)
Head and neck cancer 12 (8.7)
Colorectal cancer 8 (5.8)
Breast cancer 10 (7.2)
Esophageal cancer 4 (2.9)
Stomach cancer 4 (2.9)
Thyroid cancer 1 (0.7)
Pancreatic cancer 6 (4.3)
Cervical cancer 4 (2.9)
Ovarian cancer 4 (2.9)
Uterine cancer 6 (4.3)
Prostate cancer 2 (1.4)
Gastrointestinal stromal tumor 1 (0.7)
Brain cancer 1 (0.7)










2003 to 2006 38 (27.5)
2007 to 2010 86 (62.3)
Sample size
Less than 24 30 (21.7)
25 to 49 50 (36.2)
50 to 99 31 (22.5)
More than 100 27 (19.5)
Study type
Comparative study 68 (49.3)
Non-comparative study 70 (50.7)
Study design
Prospective study 35 (25.4)
Retrospective study 103 (74.6)
Funding source
Description included 17 (12.3)
No description 121 (87.7)
Table 1 Characteristics of included studies by year of
application/revision of the insurance service (Continued)
Index type
Indexed in MEDLINE 69 (50.0)
Not indexed in MEDLINE 69 (50.0)
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This study is the first systematic review of the character-
istics and quality of diagnostic accuracy studies of PET
conducted in Japan. Although a total of 138 Japanese
studies involving PET were identified, half of them were
not indexed in MEDLINE. Although a potential overlap
of study subjects may exist among several studies, this
could not be taken into consideration due to a lack of
information about the study participants in some stud-
ies. Also, papers with different aims and methods were
considered as independent studies. In contrast, the total
number of studies reviewed in a HTA report in the UK
was 158 and included 6 non-English studies indexed in
international databases [4]. Also, languages in the pri-
mary study selection were limited to several European
languages in the Belgian report [6,10]. Therefore, non-
indexed Japanese studies or studies written in Japanese
would likely be missed from international HTA reports.
Malignant neoplasm was the target disease most fre-
quently covered by Japanese studies (Table 1). This is a
similar finding to previous international studies [4,10].
Fifty-eight percent of Japanese studies had a sample size
less than 50. The estimates of accuracy in small studies are
often inexact and their results have little generalizability
for target patients [20]. Also, Bachmann et al. estimated
that the median number of patients with or without a tar-
get condition necessary to calculate valid sensitivity and
specificity of diagnostic accuracy is 49 and 76, respectively.
The sample size for most international PET studies was
also less than 100 [4,6,10]. In addition, approximately 90%
of Japanese studies did not include information about
funding sources. A systematic review of conflict of inter-
ests highlighted that systematic biases support products
created by the funder [21], thus implying that hidden
conflicts of interest may be present among the Japanese
studies.
Our study showed that the mean quality score was 6.7
(e.g., a full score is 14), and 33% of Japanese PET studies
were of high quality, as indicated by the quality score of
more than 8. These results were similar to those of
several recent systematic reviews [22,23]. Also, a high
risk of bias was observed in six items including adequate
spectrum, adequate reference standard, and absence of
verification bias, among others (Figure 2). This result indi-
cates that the Japanese studies have numerous biases and
are of relatively low quality, which is limitedly applicable
to PET use in clinical settings. For example, PET studies
Figure 2 Quality of diagnostic studies assessed by QUADAS.
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technology assessments (i.e., quality score less than eight)
[18], or critically examined in clinical recommendations
[4,6,10]. Therefore, studies of low quality will neither be
used nor reflected in clinical guidelines and health pol-
icies. Moreover, the quality of test studies is extremely
important as a basis for further evaluation for clinical de-
cision making and health outcomes [24,25]. Greater im-
provement of the quality of test studies is urgently needed.
Factors related to the methodological quality, target
disease, publication year, and study design were deter-
mined by multiple logistic regression analysis (Table 2).Figure 3 Comparison of quality between MEDLINE-indexed and non-iPrior to 2002 when PET examination was first included
in the National Health Insurance, the quality of studies
was high. This may be because that prior to the applica-
tion of insurance coverage, PET researchers, related
academies and industries proactively and rigorously con-
ducted and published many PET studies to encourage
and persuade the government to include PET testing in
the insurance scheme, as well as to promote the
utilization of PET testing after its inclusion in the insur-
ance coverage. These efforts to promote PET testing
seem to have had a positive influence on maintaining
the methodological quality of the studies and overcomingndexed studies.
Table 2 Factors related to methodological quality
Variables Number of studies Odds ratio 95% confidence interval p value
Diseases
Respiratory cancer 30 Ref.
Gastrointestinal cancer 7 0.98 0.13 to 7.44 1.0
Gynecological cancer 19 0.38 0.09 to 1.56 0.2
Head and neck cancer 14 0.39 0.08 to 1.80 0.2
Breast cancer 10 0.23 0.04 to 1.46 0.1
Others 58 0.23 0.07 to 0.76 0.02
Publication year
2002 14 Ref.
2003 to 2006 38 0.11 0.02 to 0.53 0.01
2007 to 2010 86 0.30 0.07 to 1.30 0.1
Sample size
Less than 24 30 Ref.
25 to 49 50 1.43 0.47 to 4.35 0.5
50 to 99 31 1.00 0.28 to 3.58 1.0
Over 100 27 0.53 0.13 to 2.12 0.4
Study design
Retrospective study 103 Ref.
Prospective study 35 2.78 1.05 to 7.35 0.04
Funding source
No description 121 Ref.
Description included 17 2.9 0.78 to 10.73 0.1
Index type
Not indexed in MEDLINE 69 Ref.
Indexed in MEDLINE 69 0.84 0.34 to 2.10 0.7
Comparative study
No 72 Ref.
Yes 66 1.53 0.64 to 3.62 0.3
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have been conducted mainly in the area of oncology, par-
ticularly in respiratory cancer, the quality of studies based
on target disease will improve over time as research appli-
cations of PET expand into other areas. Our results are
consistent with previous research which highlighted that
prospective studies are favorable for reducing biases [26].
Our assessment of the characteristics and quality of
Japanese PET studies demonstrates that efforts to educate
researchers, provide incentives, and establish systems for
conducting diagnostic studies are needed to encourage
investigators to comply with existing methodological stan-
dards. Low quality of reporting was found to be a signifi-
cant obstacle in the evaluation of quality, and therefore
the risk of bias remained unclarified in this study. As
many studies have limited applicability in clinical practice
and health policy, their inclusion might be misleading in
some cases. In this study, a high proportion of ‘unclear’results were observed in several items of risk of bias
(Figure 2), which proved difficult for reviewers to evalu-
ate the actual quality of the studies. This result is also
reported in several systematic reviews [18,19]. Concerns
about the quality of reporting of diagnostic studies led
to the endorsement of the STARD statement [27]. Since
the publication of this statement, the quality of report-
ing of diagnostic accuracy studies has slightly improved
[28]. To advance the quality of reporting in Japan, efforts
are required to raise awareness of the STARD statement
and to encourage publishers of Japanese scientific journals
to adopt the statement in their instructions to authors.
Conversely, 34.9% of studies not indexed in MEDLINE
and 30.4% of the indexed studies were of high quality
with a quality score of eight or higher. There was no
significant difference in the total quality score between
the two groups, even though a significant difference
was observed in several items between them (Figure 3).












PET use in oncology
Lung cancer 30 7.2 11 (37) 8 (27) ○ (SNP, NCLC) Yes (SNP, NCLC)
Lymphoma 5 6 4 (80) 3 (60) × No
Head and neck cancer 12 6.7 5 (42) 5 (42) ○ Yes
Colorectal cancer 8 6.6 3 (38) 4 (50) × No
Breast cancer 10 5.7 4 (40) 3 (30) × No
Esophageal cancer 4 8.8 3 (75) 1 (25) Lack of evidence No
Stomach cancer 4 5.8 2 (50) 3 (75) Lack of evidence -
Pancreatic cancer 6 8.7 4 (67) 4 (67) Unclear Yes
Cervical cancer 4 7.5 3 (75) 3 (75) Lack of evidence -
Ovarian cancer 4 6.3 4 (100) 3 (75) ○ -
Uterine cancer 6 7.8 3 (50) 0 (0) Lack of evidence -
*Positive: PET(/CT) was superior to other competitive diagnostic technologies.
○, evidence for diagnostic accuracy; ×, non-evidence for diagnostic accuracy; SNP, solitary pulmonary nodule; NCLC, non-small-cell lung cancer.
Nomura et al. EJNMMI Research  (2015) 5:6 Page 8 of 9After adjusting for other factors in a logistic regression
model, the overall quality was not significantly different
between indexed PET studies and those not indexed in
MEDLINE (Table 2). This result suggests that non-
indexed Japanese studies should be included in system-
atic reviews as well as both international and Japanese
databases in order to prevent the exclusion of high-quality
Japanese PET studies. In addition, excluding Japanese
studies may introduce a language bias and lead to errone-
ous conclusions.
The search and collection of non-English language pa-
pers is important to minimize language bias [29]. In
conducting systematic reviews, international collaboration
in the area where language bias might occur could be a
practical and feasible solution for minimizing language
bias. On the other hand, non-English-speaking researchers
should also be encouraged to publish original studies in
English in a journal indexed in international databases.
Finally, only 47.8% of Japanese studies employed com-
parators (i.e., competitive diagnostic technologies such
as MRI or CT) to evaluate diagnostic accuracy of PET.
Of this percentage, only 23 studies performed statistical
analysis. As the diagnostic accuracy of non-comparative
studies often differs to that of comparative studies [30],
the conclusions of the Japanese studies should be care-
fully interpreted. However, there has been no mention of
this issue even in systematic reviews and HTA reports of
PET studies [4,22,23,30]. In addition, only 6.9% of non-
comparative studies performed simple comparisons with
the results obtained from literature surveys.
These issues might influence the discrepancy of conclu-
sions between Japanese studies and international assess-
ments. For discrepancies found in the coverage of disease
areas, Japanese studies could serve as supplementary in-
formation for the conclusions or recommendations ofinternational assessments to prevent language bias, since
international assessments do not include most Japanese
studies. However, further systematic examination would
be needed to integrate the information and assess the in-
fluence on conclusions and recommendations, since there
is no explicit or standardized guideline for integrating
these conclusions or recommendations.
On the other hand, in regard to the disease areas where
only Japanese studies were available, the application of the
Japanese National Health Insurance was based on a small
number of studies with relatively low quality scores. In the
case of uterine cancer, there is no positive conclusion. In
Japan, since there has been neither comprehensive HTA
nor guidance based on systematic reviews, further exami-
nations would be required for health and clinical policy.
Conclusions
The Japanese studies covered a wide range of target dis-
eases, which were not evaluated by the HTA and the sys-
tematic review. For a practical solution of these issues,
Japanese studies or other language studies should be com-
prehensively included and simultaneously evaluated when
conducting HTA or systematic reviews.
Diverse factors such as study design, conduct, analysis,
and reporting of PET studies are related to the quality,
number, and progress of PET studies in Japan. Greater
efforts are required to set and implement feasible strategies
for improving Japanese PET studies under the collective ac-
tion of all stakeholders.
Additional files
Additional file 1: Table S1. Search strategy for article selection on Ovid
MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)
and Ovid OLDMEDLINE(R) 1946 to Present with Daily Update.
Nomura et al. EJNMMI Research  (2015) 5:6 Page 9 of 9Additional file 2: Table S2. Search strategy for article selection on
Ichushi web.
Additional file 3: Table S3. Detailed descriptions of QUADAS items.
Abbreviations
HTA: health technology assessment; PET: positron emission tomography;
QUADAS: quality assessment of diagnostic accuracy studies.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AH initiated and oversaw the project. All authors were responsible for the
study concept and design. SN and MS acquired the data. SN, KM, DY, EO,
and AH conducted the quality assessment. The manuscript drafted by SN
was discussed and critically revised by AH and KS. KS gave administrative
and technical support and supervision. All authors approved the final draft of
the manuscript.
Acknowledgements
There are no funding sources for this study.
Author details
1Department of Global Health Policy, Graduate School of Medicine, The
University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
2Institute of Healthcare Technology Assessment, 2-24-10, Shomachi,
Tokushima 770-0044, Japan. 3Present affiliation: Department of Epidemiology
and Biostatistics, School of Public Health, Imperial College London, Norfolk
Place, London W2 1PG, UK.
Received: 27 November 2014 Accepted: 24 January 2015
References
1. Juweid ME, Cheson BD. Positron-emission tomography and assessment of
cancer therapy. N Eengl Med. 2006;354:496–507.
2. Czernin J, Phelps ME. Positron emission tomography scanning: current and
future applications. Annu Rev Med. 2002;53:89–112.
3. Rama KR, Poovali S, Apsingi S. Quality of reporting of orthopaedic
diagnostic accuracy studies is suboptimal. Clin Orthop Relat Res.
2006;447:237–46.
4. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness
of positron emission tomography imaging in selected cancers. Health
Technl Assess. 2007;11:iii–iv. xi–267.
5. Evans WK, Laupacis A, Gulenchyn KY, Levin L, Levine M. Evidence-based
approach to the introduction of positron emission tomography in Ontario,
Canada. J Clin Oncol. 2009;27:5607–13.
6. Cleemput I, Dargent G, Poelmans J, Camberlin C, Van den Bruel A,
Ramaekers D. Positron emission tomography in Belgium. Brussels: Belgian
Health Care Knowledge Centre (KCE); 2005.
7. Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J.
Development and validation of methods for assessing the quality of
diagnostic accuracy studies. Health Technl Assess. 2004;8(iii):1–234.
8. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al.
Towards complete and accurate reporting of studies of diagnostic accuracy.
the STARD initiative. Croat Med J. 2003;44:635–8.
9. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development
of QUADAS: a tool for the quality assessment of studies of diagnostic
accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
10. Vlayen J, Stordeur S, Van den Bruel A, Mambourg FEM. Positron emission
tomography (PET) in Belgium: an update. Brussels: Belgian Health Care
Knowledge Centre (KCE); 2009.
11. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al.
Recommendations on the use of 18 F-FDG PET in oncology. J Nuc Med.
2008;49:480–508.
12. Positron Emission Tomography (PET) scanners – OECD. 2013 [http://stats.
oecd.org/Index.aspx]
13. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J.
Evaluation of QUADAS, a tool for the quality assessment of diagnostic
accuracy studies. BMC Med Res Methodol. 2006;6:9.14. Reitsma JB, Rutjes AWS, Whiting P, Vlassov VV, Leeflang MMG, Deeks JJ.
Chapter 9: assessing methodological quality. In: Deeks JJ, Bossuyt PM,
Gatsonis C, editors. Cochrane Handbook for Systematic Reviews of
Diagnostic Test Accuracy. Oxford: The Cochrane Collaboration; 2009.
p. 1–27.
15. Hegedus EJ, Goode A, Campbell S, Morin A, Tamaddoni M, Moorman 3rd
CT, et al. Physical examination tests of the shoulder: a systematic review
with meta-analysis of individual tests. Br J Sports Med. 2008;42:80–92.
discussion 92.
16. Yu YH, Liang C, Yuan XZ. Diagnostic value of vacuum-assisted breast biopsy
for breast carcinoma: a meta-analysis and systematic review. Breast Cancer
Res Treat. 2010;120:469–79.
17. Gabriel A-C, ¡ngel J, Juan J, Luis R, Hernando R, RubÈn S-B. Diagnostic accuracy
of ultrasound for detecting posterior ligamentous complex injuries of
the thoracic and lumbar spine: a systematic review and meta-analysis.
J Craniovertebr Junct Spine. 2013;4:25–31.
18. Mujoomdar M, Moulton KEN. Positron emission tomography (PET) in
oncology: a systematic review of clinical effectiveness and indications for
use. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010.
19. Hailey D. Toward transparency in health technology assessment: a checklist
for HTA reports. Int J Technol Assess Health Care. 2003;19:1–7.
20. Bachmann LM, Puhan MA, ter Riet G, Bossuyt PM. Sample sizes of studies
on diagnostic accuracy: literature survey. BMJ. 2006;332:1127–9.
21. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry
sponsorship and research outcome and quality: systematic review.
BMJ. 2003;326:1167–70.
22. Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, den Bos
IC P-v, et al. Comparison of modern and conventional imaging techniques
in establishing multiple myeloma-related bone disease: a systematic review.
Br J Haematol. 2013;162:50–61.
23. Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases
of gastric cancer: a systematic review. BMC Gastroenterol. 2011;11:19.
24. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis
Making. 1991;11:88–94.
25. Pearl WS. A hierarchical outcomes approach to test assessment. Ann Emerg
Med. 1999;33:77–84.
26. Mallett S, Deeks JJ, Halligan S, Hopewell S, Cornelius V, Altman DG.
Systematic reviews of diagnostic tests in cancer: review of methods and
reporting. BMJ. 2006;333:413.
27. Smidt N, Overbeke J, de Vet H, Bossuyt P. Endorsement of the STARD
statement by biomedical journals: survey of instructions for authors. Clin
Chem. 2007;53:1983–5.
28. Smidt N, Rutjes AW, van der Windt DA, Ostelo RW, Bossuyt PM, Reitsma JB,
et al. The quality of diagnostic accuracy studies since the STARD statement:
has it improved? Neurology. 2006;67:792–7.
29. Centre for Reviews and Dissemination. Systematic review: CRD’s guidance
for undertaking reviews in health care. York: University of York; 2009.
30. Takwoingi Y, Leeflang MM, Deeks JJ. Empirical evidence of the importance
of comparative studies of diagnostic test accuracy. Ann Intern Med.
2013;158:544–54.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
